Cargando…
Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
SIMPLE SUMMARY: Novel pharmacological approaches are needed to improve treatments of advanced cancers, despite the considerable benefit of immunotherapy. New drugs are searched for to complement the activity of monoclonal antibodies targeted to the PD-1/PD-L1 immune checkpoint. Here, we have identif...
Autores principales: | Thuru, Xavier, Magnez, Romain, El-Bouazzati, Hassiba, Vergoten, Gérard, Quesnel, Bruno, Bailly, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322126/ https://www.ncbi.nlm.nih.gov/pubmed/35884428 http://dx.doi.org/10.3390/cancers14143368 |
Ejemplares similares
-
A Potential Off-Target Effect of the Wnt/β-Catenin Inhibitor KYA1797K: PD-L1 Binding and Checkpoint Inhibition
por: Thuru, Xavier, et al.
Publicado: (2023) -
PD-1/PD-L1 binding studies using microscale thermophoresis
por: Magnez, Romain, et al.
Publicado: (2017) -
Novel PD-L1-Targeted Phenyl-Pyrazolone Derivatives with Antioxidant Properties
por: Regnault, Romain, et al.
Publicado: (2023) -
Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
por: Bailly, Christian, et al.
Publicado: (2021) -
Antioxidant Properties and Aldehyde Reactivity of PD-L1 Targeted Aryl-Pyrazolone Anticancer Agents
por: Leleu-Chavain, Natascha, et al.
Publicado: (2022)